Cited by 397Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 94 of the 101 references it cites were found in a registry or an index.

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Open access

Grossberg, George T·2003·Current Therapeutic Research

DOI 10.1016/s0011-393x(03)00059-6PMC PMC4052996

Open this paper in CoChat — free account Open PDF

Abstract

Background Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. In addition to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.Objective The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacologic differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clinical practice.Methods Using published literature collected over time by the author, a review was conducted, focusing on the pharmacology and clinical data of donepezil, galantamine, and rivastigmine.Results All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large. These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit. To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clinical practice, consisting of a "start low, go slow" procedure with a minimum of 4 weeks between dose increases. After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).Conclusions ChE inhibitors provide symptomatic benefit in AD across key symptom domains. Factors influencing the safety, tolerability, and efficacy of these agents in clinical practice include ChE enzymes inhibited, brain and brain-region ChE selectivity, and metabolism route. Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0011-393x(03)00059-6

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Physicians Desk Reference
Arky, R. A. (1994) · Cited by 2,632
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Molecular and cellular biology of cholinesterases
Massoulié, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F.-M. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90040-y · Cited by 1,214
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117

Show all 101 references

Research works printed but not linked: 10

McRae, 1999, A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: Side effects and concomitant medication use, Int J Neuropharmacol, 2, S176
Shua-Haim, 2001, Safety and tolerability of slow titration of rivastigmine (Exelon) in the treatment of patients with Alzheimer's disease (AD): An overall analysis of two prospective studies, J Am Geriatr Soc, 49, S76
Vellas, 1998, Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients, Int J Geriatr Psychopharmacol, 1, 140
Schneider, 1998, Systematic review of efficacy of rivastigmine for patients with Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, S26
Anand, 2000, Dose-response effect of rivastigmine in the treatment of Alzheimer's disease, Int J Geriatr Psychopharmacol, 2, 68
Cummings, 2000, Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial, Neurology, 54, A468
Sanders, 2001, Donepezil in dementia with Lewy bodies: Treatment and withdrawal, Int Psychogeriatr, 13, 224
Raskind M, Truyen L. Galantamine has long-term cognitive benefits in Alzheimer's disease—an analysis of responder rates at 36 months. Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; April 3–6, 2003; Geneva, Switzerland.
Grossberg, 2001, Rivastigmine in Alzheimer's disease: Efficacy over 2 years compared with historical controls, Int Psychogeriatr, 13, 237
Barber, 1996, Butyrylcholinesterase alters the aggregation state of Aβ amyloid, Proc Soc Neurosci, 22, 1172

Sorted by citations

Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomová, K., Alomar, S. Y., Valko, R., Líška, J., Nepovimová, E., Kuča, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 449
Expression and Function of the Cholinergic System in Immune Cells
Fujii, T., Mashimo, M., Moriwaki, Y., Misawa, H., Ono, S., Horiguchi, K., & Kawashima, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01085 · Cited by 385
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R.-N., Bild, V., Chiriac, S. I. B., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 307
Rivastigmine for Alzheimer's disease
Birks, J., Evans, J. G., Iakovidou, V., & Tsolaki, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub2 · Cited by 295
Review on plants with CNS-effects used in traditional South African medicine against mental diseases
Stafford, G. I., Pedersen, M. E., van Staden, J., & Jäger, A. K. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.08.010 · Cited by 256
Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters
Shah, B. M., Khunt, D., Bhatt, H., Misra, M., & Padh, H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.07.002 · Cited by 237
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease
Holper, L., Ben‐Shachar, D., & Mann, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0090-0 · Cited by 236
Rivastigmine Transdermal Patch
Dhillon, S. (2011) · Drugs · doi:10.2165/11206380-000000000-00000 · Cited by 215
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease
Haake, A., Nguyen, K. T., Friedman, L. G., Chakkamparambil, B., & Grossberg, G. T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1721456 · Cited by 182
Self-citation
Effects of medicinal plants on Alzheimer's disease and memory deficits
Akram, M., & Nawaz, A. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205108 · Cited by 187
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Rivastigmine for Alzheimer's disease
Birks, J., Evans, J. G., Iakovidou, V., & Tsolaki, M. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191 · Cited by 159
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
Khoury, R., Rajamanickam, J., & Grossberg, G. T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617750555 · Cited by 156
Self-citation
Discovery and Structure–Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening
Dighe, S. N., Deora, G. S., la Mora, E. D., Nachon, F., Chan, S., Parat, M., Brazzolotto, X., & Ross, B. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00356 · Cited by 157
Acetylcholinesterase and Its Inhibition in Alzheimer Disease
Lane, R. M., Kivipelto, M., & Greig, N. H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200405000-00011 · Cited by 149
Survey of 55 Turkish Salvia taxa for their acetylcholinesterase inhibitory and antioxidant activities
Şenol, F. S., Orhan, İ. E., Celep, F., Kahraman, A., Doğan, M., Yılmaz, G., & Şener, B. (2009) · Food Chemistry · doi:10.1016/j.foodchem.2009.09.066 · Cited by 143
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
Therapeutic Potentials of Microalgae in the Treatment of Alzheimer’s Disease
Olasehinde, T. A., Olaniran, A. O., & Okoh, A. I. (2017) · Molecules · doi:10.3390/molecules22030480 · Cited by 144
Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization
Shah, B. M., Misra, M., Shishoo, C. J., & Padh, H. (2014) · Drug Delivery · doi:10.3109/10717544.2013.878857 · Cited by 136
Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients
Lefèvre, G. Y., Sedek, G., Jhee, S. S., Leibowitz, M. T., Huang, H.-L., Enz, A., Maton, S., Ereshefsky, L., Pommier, F., Schmidli, H., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100242 · Cited by 130
Anticholinesterase and antioxidant activities of Savoury (Satureja thymbra L.) with identified major terpenes of the essential oil
Öztürk, M. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.02.054 · Cited by 118
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Kabir, M. T., Uddin, M. S., Begum, M. M., Thangapandiyan, S., Rahman, M. S., Aleya, L., Mathew, B., Ahmed, M., Barreto, G. E., & Ashraf, G. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191008103141 · Cited by 119
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy
Arya, A., Chahal, R., Rao, R., Rahman, M. H., Kaushik, D., Akhtar, M. F., Saleem, A., Khalifa, S. M. A., El-Seedi, H. R., Kamel, M., et al. (2021) · Biomolecules · doi:10.3390/biom11030350 · Cited by 111
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
Feldman, H., Lane, R. M., & on behalf of the Study 304 Group (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.099424 · Cited by 107
Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode
Sawatzky, E., Wehle, S., Kling, B., Wendrich, J., Bringmann, G., Sotriffer, C., Heilmann, J., & Decker, M. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01674 · Cited by 102
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
Chemical characterization of sulfated polysaccharides from Gracilaria gracilis and Ulva lactuca and their radical scavenging, metal chelating, and cholinesterase inhibitory activities
Olasehinde, T. A., Mabinya, L. V., Olaniran, A. O., & Okoh, A. I. (2019) · International Journal of Food Properties · doi:10.1080/10942912.2019.1573831 · Cited by 96
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation
Mohammad, D., Chan, P., Bradley, J., Lanctôt, K. L., & Herrmann, N. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351540 · Cited by 84
A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos
Sereniki, A., & Vital, M. A. B. F. (2008) · Revista de Psiquiatria do Rio Grande do Sul · doi:10.1590/s0101-81082008000200002 · Cited by 121
Anti-aging effect of phlorizin on D-galactose–induced aging in mice through antioxidant and anti-inflammatory activity, prevention of apoptosis, and regulation of the gut microbiota
Chen, H., Dong, L., Chen, X., Ding, C., Hao, M., Peng, X., Zhang, Y., Zhu, H., & Liu, W. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111769 · Cited by 75
Profiling donepezil template into multipotent hybrids with antioxidant properties
Mezeiová, E., Špilovská, K., Nepovimová, E., Górecki, L., Soukup, O., Doležal, R., Maliňák, D., Janočková, J., Jun, D., Kuča, K., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1443326 · Cited by 74
Pharmacokinetic rationale for the rivastigmine patch
Cummings, J. L., Lefèvre, G. Y., Small, G. W., & Appel‐Dingemanse, S. (2007) · Neurology · doi:10.1212/01.wnl.0000281846.40390.50 · Cited by 72
Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease
Winblad, B. G., & Machado, J. C. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802542690 · Cited by 71
The Application of Seaweed Polysaccharides and Their Derived Products with Potential for the Treatment of Alzheimer’s Disease
Bauer, S., Jin, W., Zhang, F., & Linhardt, R. J. (2021) · Marine Drugs · doi:10.3390/md19020089 · Cited by 70
An Expanded Narrative Review of Neurotransmitters on Alzheimer’s Disease: The Role of Therapeutic Interventions on Neurotransmission
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
Blesa, R., Bullock, R. A., He, Y., Bergman, H., Gambina, G., Meyer, J. M., Rapatz, G., Nagel, J., & Lane, R. M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000220573.05714.ac · Cited by 65
Newly Developed Drugs for Alzheimer’s Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
Korábečný, J., Nepovimová, E., Cikánková, T., Špilovská, K., Vašková, L., Mezeiová, E., Kuča, K., & Hroudová, J. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2017.06.034 · Cited by 64
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
Bullock, R. A., Bergman, H., Touchon, J., Gambina, G., He, Y., Nagel, J., & Lane, R. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89685 · Cited by 63
Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application
Lefèvre, G. Y., Sedek, G., Huang, H. A., Saltzman, M. A., Rosenberg, M. A., Kiese, B., & Fordham, P. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297748 · Cited by 62
Molecular insights into the benefits of nicotine on memory and cognition (Review)
Alhowail, A. H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12037 · Cited by 65
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Ghrelin in Alzheimer’s disease: Pathologic roles and therapeutic implications
Jeon, S. G., Hong, S. B., Nam, Y., Tae, J., Yoo, A., Song, E. J., Kim, K. I., Lee, D., Park, J., Lee, S. M., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100945 · Cited by 60
New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease
Jalili‐Baleh, L., Nadri, H., Moradi, A., Bukhari, S. N. A., Shakibaie, M., Jafari, M., Golshani, M., Moghadam, F. H., Firoozpour, L., Asadipour, A., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.072 · Cited by 59
Nanocapsules containing Saussurea lappa essential oil: Formulation, characterization, antidiabetic, anti-cholinesterase and anti-inflammatory potentials
Lammari, N., Demautis, T., Louaer, O., Meniai, A. H., Casabianca, H., Bensouıcı, C., Devouassoux, G., Fessi, H., Bentaher, A., & Elaı̈ssari, A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120138 · Cited by 58
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 66
Acetylcholinesterase as a Multifunctional Target in Amyloid-Driven Neurodegeneration: From Dual-Site Inhibitors to Anti-Agregation Strategies
Grabowska, W. A., Bijak, M., Szelenberger, R., Gorniak, L., Podogrocki, M., Harmata, P., & Cichoń, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178726 · Cited by 65
Chemical characterization, antioxidant properties, cholinesterase inhibitory and anti-amyloidogenic activities of sulfated polysaccharides from some seaweeds
Olasehinde, T. A., Mabinya, L. V., Olaniran, A. O., & Okoh, A. I. (2019) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2019.100182 · Cited by 60
Phytochemical investigation, antioxidant and anticholinesterase activities of Ganoderma adspersum
Tel‐Çayan, G., Öztürk, M., Duru, M. E., Rehman, M. U., Adhikari, A., Türkoğlu, A., & Choudhary, M. I. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2015.07.042 · Cited by 55
Influence of Acetylcholinesterase Inhibitors Used in Alzheimer’s Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in THP-1 Macrophages under Fluoride-Induced Oxidative Stress
Goschorska, M., Gutowska, I., Baranowska‐Bosiacka, I., Piotrowska, K., Metryka, E., Safranow, K., & Chlubek, D. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16010010 · Cited by 58
Identification of embelin, a 3‐undecyl‐1,4‐benzoquinone from Embelia ribes as a multitargeted anti‐Alzheimer agent
Nuthakki, V. K., Sharma, A., Kumar, A., & Bharate, S. B. (2019) · Drug Development Research · doi:10.1002/ddr.21544 · Cited by 56
An overview of the pharmacological activities of scopoletin against different chronic diseases
Parama, D., Girisa, S., Khatoon, E., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Sethi, G., & Kunnumakkara, A. B. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106202 · Cited by 54
Design, synthesis, in silico and biological evaluations of novel polysubstituted pyrroles as selective acetylcholinesterase inhibitors against Alzheimer’s disease
Pourtaher, H., Hasaninejad, A., & Iraji, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-18224-6 · Cited by 54
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance
van Hattem, T., Verkaar, L., Krugliakova, E., Adelhöfer, N., Zeising, M., Drinkenburg, W. H. I. M., Claassen, J. A. H. R., Bódizs, R., Dresler, M., & Rosenblum, Y. (2024) · Physiology · doi:10.1152/physiol.00019.2024 · Cited by 57
From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease
Chierrito, T. P. C., Mantoani, S. P., Roca, C., Requena-Triguero, C., Sebastián-Pérez, V., Ordoñez, W. O. C., Moreira, N. C. D. S., Pérez, C., Sakamoto‐Hojo, E. T., Takahashi, C. S., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.051 · Cited by 54
Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 60
Synthesis and biological evaluation of indoloquinoline alkaloid cryptolepine and its bromo-derivative as dual cholinesterase inhibitors
Nuthakki, V. K., Mudududdla, R., Sharma, A., Kumar, A., & Bharate, S. B. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103062 · Cited by 52
Potential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants
Amat-ur-Rasool, H., Symes, F., Tooth, D., Schaffert, L.-N., Elmorsy, E. M., Ahmed, M., Hasnain, S., & Carter, W. G. (2020) · Biomolecules · doi:10.3390/biom10111556 · Cited by 55
Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo
Scheiner, M., Dolles, D., Gunesch, S., Hoffmann, M., Nabissi, M., Marinelli, O., Naldi, M., Bartolini, M., Petralla, S., Poeta, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00623 · Cited by 49
The impact of chelating compounds on Cu2+, Fe2+/3+, and Zn2+ ions in Alzheimer's disease treatment
Mazur, T., Malik, M., & Bieńko, D. C. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112601 · Cited by 54
Anti-Acetylcholinesterase and Antioxidant Assets of the Major Components (Salicin, Amentoflavone, and Chlorogenic Acid) and the Extracts of Viburnum opulus and Viburnum lantana and Their Total Phenol and Flavonoid Contents
Orhan, İ. E., Altun, M. L., Yılmaz, B. S., & Çitoğlu, G. S. (2010) · Journal of Medicinal Food · doi:10.1089/jmf.2010.0053 · Cited by 49
Le test des 5 mots : validité dans la détection de la maladie d’Alzheimer dans la population générale
Cowppli-Bony, P., Fabrigoule, C., Letenneur, L., Ritchie, K. A., Alpérovitch, A., Dartigues, J., & Dubois, B. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85194-x · Cited by 49
An Overview of the Evidence and Mechanism of Drug–Herb Interactions Between Propolis and Pharmaceutical Drugs
Hossain, S., Yousaf, M., Liu, Y., Chang, D., & Zhou, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876183 · Cited by 47
Coumarins fromPeucedanum ostruthium. as Inhibitors of Acetylcholinesterase
Urbain, A., Marston, A., & Hostettmann, K. (2005) · Pharmaceutical Biology · doi:10.1080/13880200500382720 · Cited by 47
Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance
Núñez, C., Callén, A., Lombardini, F., Compta, Y., Stephan‐Otto, C., & Initiative, A. D. N. (2020) · Annals of Neurology · doi:10.1002/ana.25741 · Cited by 47
Therapeutic Efficacies of Berberine against Neurological Disorders: An Update of Pharmacological Effects and Mechanisms
Shou, J., & Shaw, P. (2022) · Cells · doi:10.3390/cells11050796 · Cited by 48
Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer’s Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?
Jha, S. K., Jha, N. K., Kumar, D., Sharma, R., Shrivastava, A., Ambasta, R. K., & Kumar, P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160623 · Cited by 48
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
Parsons, C., Lim, W. Y., Loy, C. T., McGuinness, B., Passmore, P., Ward, S. A., & Hughes, C. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009081.pub2 · Cited by 49
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands
Rodríguez‐Soacha, D. A., Scheiner, M., & Decker, M. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.040 · Cited by 44
Synthesis and Biological Evaluation of Some Pyrazoline Derivatives Bearing a Dithiocarbamate Moiety as New Cholinesterase Inhibitors
Altıntop, M. D., Özdemır, A., Kaplancıklı, Z. A., Turan‐Zitouni, G., Temel, H. E., & Çiftçi, G. A. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201200384 · Cited by 43
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
Application of GC, GC-MSD, ICP-MS and Spectrophotometric Methods for the Determination of Chemical Composition and In Vitro Bioactivities of Chroogomphus rutilus: The Edible Mushroom Species
Çayan, F., Tel‐Çayan, G., Duru, M. E., Öztürk, M., Türkoğlu, A., & Harmandar, M. (2013) · Food Analytical Methods · doi:10.1007/s12161-013-9644-2 · Cited by 41
Peptide-Based Acetylcholinesterase Inhibitor Crosses the Blood-Brain Barrier and Promotes Neuroprotection
Mondal, P., Gupta, V., Das, G., Pradhan, K., Khan, J., Gharai, P. K., & Ghosh, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00253 · Cited by 45
Ziziphus nummularia: A Comprehensive Review of Its Phytochemical Constituents and Pharmacological Properties
Mesmar, J. E., Abdallah, R., Badran, A., Maresca, M., Shaito, A. A., & Baydoun, E. (2022) · Molecules · doi:10.3390/molecules27134240 · Cited by 40
A novel pharmacological activity of caffeine in the cholinergic system
Fabiani, C., Murray, A. P., Corradi, J., & Antollini, S. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.041 · Cited by 40
Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study
Rochon, P. A., Gruneir, A., Bell, C. M., Savage, R., Gill, S. S., Wu, W., Giannakeas, V., Stall, N. M., Seitz, D. P., Normand, S. T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205524 · Cited by 40
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 39
Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation
Zha, G., Zhang, C., Qin, H., Jantan, I., Sher, M., Amjad, M. W., Hussain, M. A., Hussain, Z., & Bukhari, S. N. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.015 · Cited by 39
Isoquinoline derivatives as potential acetylcholinesterase inhibitors
Markmee, S., Ruchirawat, S., Prachyawarakorn, V., Ingkaninan, K., & Khorana, N. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.067 · Cited by 39
Isolation, crystal structure determination and cholinesterase inhibitory potential of isotalatizidine hydrate from Delphinium denudatum
Ahmad, H., Ahmad, S., Khan, E., Shahzad, A., Ali, M., Tahir, M. N., Shaheen, F., & Ahmad, M. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1240207 · Cited by 38
Aptamer-functionalized magnetic nanoparticles conjugated organic framework for immobilization of acetylcholinesterase and its application in inhibitors screening
Zhao, L., Yang, G. H., Li, L., Zhu, C., Ma, Y., & Qu, F. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.10.024 · Cited by 38
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?
Mitić, M., & Pašti, T. D. L. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1931681 · Cited by 39
Novel Vilazodone–Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation
Li, X., Wang, H., Xu, Y., Liu, W., Gong, Q., Wang, W., Qiu, X., Zhu, J., Mao, F., Zhang, H., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00259 · Cited by 37
Carbamate as a potential anti‐Alzheimer's pharmacophore: A review
Singh, Y. P., Kumar, N., Chauhan, B. S., & Garg, P. (2023) · Drug Development Research · doi:10.1002/ddr.22113 · Cited by 36
A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017
Andrisano, V., Naldi, M., Simone, A. D., & Bartolini, M. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1476494 · Cited by 35
Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation
Kapil, R., Dhawan, S., Beg, S., & Singh, B. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.665926 · Cited by 35
Novel dehydroabietylamine derivatives as potent inhibitors of acetylcholinesterase
Wiemann, J., Loesche, A., & Csük, R. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.07.013 · Cited by 34
Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity
Markowicz-Piasecka, M., Sikora, J., Mateusiak, Ł., Mikiciuk-Olasik, E., & Huttunen, K. M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7303096 · Cited by 32
Innovative approaches to Alzheimer's therapy: Harnessing the power of heterocycles, oxidative stress management, and nanomaterial drug delivery system
Umar, M., Rehman, Y., Ambreen, S., Mumtaz, S. M., Shaququzzaman, M., Alam, M. M., & Ali, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102298 · Cited by 33
Anti‐cholinesterase and antioxidant properties of alkaloid and phenolic‐rich extracts from pawpaw (Carica papaya) leaf: A comparative study
Adedayo, B. C., Oyeleye, S. I., Okeke, B. M., & Oboh, G. (2020) · Flavour and Fragrance Journal · doi:10.1002/ffj.3615 · Cited by 33
Synthesis of New Quinoline-Piperonal Hybrids as Potential Drugs against Alzheimer’s Disease
Brum, J. D. O. C., Neto, D. C. F., de Almeida, J. S. F. D., Lima, J. A., Kuča, K., França, T. C. C., & Figueroa‐Villar, J. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163944 · Cited by 31
Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer’s Disease: Recent Trends and Future Development
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 33
Evaluation of Cholinesterase Inhibitory and Antioxidant Activities of Wild and Cultivated Samples of Sage ( Salvia fruticosa ) by Activity-Guided Fractionation
Şenol, F. S., Orhan, İ. E., Erdem, S. A., Kartal, M., Şener, B., Kan, Y., Celep, F., Kahraman, A., & Doğan, M. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2010.0158 · Cited by 31
Phenothiazine‐based chalcones as potential dual‐target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO‐A, MAO‐B)
Yamalı, C., Engin, F. S., Bilginer, S., Tugrak, M., Özgün, D. Ö., Ozli, G., Levent, S., Sağlık, B. N., Özkay, Y., & Gul, H. I. (2020) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4156 · Cited by 30
Pathogenesis of Alzheimer’s Disease and Diversity of 1,2,3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential
Singh, A., Singh, K., Kaur, J., Kaur, R., Sharma, A., Kaur, J., Kaur, U., Chadha, R., & Bedi, P. M. S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00393 · Cited by 30
Rivastigmine in vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1399 · Cited by 30
Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamine‐induced amnesia in mice
Martini, F., Pesarico, A. P., Brüning, C. A., Zeni, G. R., & Nogueira, C. W. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26731 · Cited by 29
Beetroot supplemented diet exhibit anti-amnesic effect via modulation of cholinesterases, purinergic enzymes, monoamine oxidase and attenuation of redox imbalance in the brain of scopolamine treated male rats
Olasehinde, T. A., Oyeleye, S. I., Ibeji, C. U., & Oboh, G. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1831260 · Cited by 30

Authors: Grossberg, G. T.
Affiliations: Saint Louis University (US)
Corresponding author: Grossberg, George T
ORCID: Grossberg, George T
Venue: Current Therapeutic Research
Publisher: Elsevier BV
Published: 2003-04
Volume: 64
Issue: 4
Pages: 216-235
ISSN: 0011-393X (ISSN-L)
DOI: 10.1016/s0011-393x(03)00059-6
PMC: PMC4052996
OpenAlex: W170237590
Cited by: 384
References: 101
Citations by year: 2026: 26 · 2025: 45 · 2024: 72 · 2023: 41 · 2022: 28 · 2021: 27 · 2020: 20 · 2019: 24 · 2018: 19 · 2017: 14 · 2016: 11 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 5
FWCI: 3.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Therapeutic Research (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Novartis Pharma
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cholinesterase inhibitors, Alzheimer's disease, donepezil, galantamine, rivastigmine, acetylcholinesterase inhibitors, butyrylcholinesterase inhibitors, dose escalation, safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks